Current Neurology and Neuroscience Reports

, Volume 11, Issue 4, pp 379–384 | Cite as

Gastrointestinal Features of Parkinson’s Disease



Gastrointestinal (GI) symptoms are among the most common nonmotor manifestations of Parkinson’s disease (PD), and they have many important ramifications for patients. The purpose of this review is to raise awareness of the full spectrum of GI symptoms in PD which include weight loss, sialorrhea, dysphagia, nausea, constipation, and defecatory dysfunction. We will discuss their practical significance, and outline a clear approach to their evaluation and management. A brief discussion about the impacts of commonly used medical and surgical PD therapies on GI symptom manifestation is also included.


Gastrointestinal Nonmotor symptoms Parkinson’s disease Weight loss Sialorrhea Dysphagia Aspiration Gastroparesis Nausea Vomiting Bloating Reflux Early satiety Constipation Defecatory dysfunction Laxatives Glycopyrrolate Atropine Ipratropium bromide Botulinum toxin Polyethylene glycol Psyllium Domperidone Apomorphine 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003;2:107–16.PubMedCrossRefGoogle Scholar
  2. 2.
    • Pfeiffer RF: Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2011;17:10–15. This is an excellent review of the clinical aspects of GI dysfunction in PD.PubMedCrossRefGoogle Scholar
  3. 3.
    Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J Neurol Sci. 2010;289:69–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson’s disease. J Neural Transm. 2008;115:443–60.PubMedCrossRefGoogle Scholar
  5. 5.
    • Lebouvier T, Chaumette T, Paillusson S, et al.: The second brain and Parkinson’s disease. Eur J Neurosci. 2009;30:735–41. This is an excellent review of available studies on the enteric nervous system in PD patients and in animal models of the disease.PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology. 1992;42:726–32.PubMedGoogle Scholar
  7. 7.
    Li H, Zhang M, Chen L, et al. Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord. 2010;25(16):2740–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Visser M, Van Rooden SM, Verbaan D, et al. A comprehensive model of health-related quality of life in Parkinson’s disease. J Neurol. 2008;255:1580–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s Disease. Auton Neurosci. 2001;92:76–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson’s disease. Ann Neurol. 1986;19:283–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc. 1987;35:683–4.PubMedGoogle Scholar
  13. 13.
    Caplan LH, Jacobson HG, Rubinstein BM, et al. Megacolon and Volvulus in Parkinson’s Disease. Radiology. 1965;85:73–9.PubMedGoogle Scholar
  14. 14.
    Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology. 1987;37:1253–5.PubMedGoogle Scholar
  15. 15.
    Bushmann M, Dobmeyer SM, Leeker L, et al. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology. 1989;39:1309–14.PubMedGoogle Scholar
  16. 16.
    Bird MR, Woodward MC, Gibson EM, et al. Asymptomatic swallowing disorders in elderly patients with Parkinson’s disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing. 1994;23:251–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Guneysel O, Onultan O, Onur O. Parkinson’s disease and the frequent reasons for emergency admission. Neuropsychiatr Dis Treat. 2008;4:711–4.PubMedGoogle Scholar
  18. 18.
    Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology. 1988;38:419–21.PubMedGoogle Scholar
  19. 19.
    Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson’s disease: patients with and without response fluctuations. Neurology. 1996;46:1051–4.PubMedGoogle Scholar
  20. 20.
    Djaldetti R, Achiron A, Ziv I, et al. First emergence of “delayed-on” and “dose failure” phenomena in a patient with Parkinson’s disease following vagotomy. Mov Disord. 1994;9:582–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Abbott RA, Cox M, Markus H, et al. Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr. 1992;46:879–84.PubMedGoogle Scholar
  22. 22.
    Beyer PL, Palarino MY, Michalek D, et al. Weight change and body composition in patients with Parkinson’s disease. J Am Diet Assoc. 1995;95:979–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Durrieu G, Llau ME, Rascol O, et al. Parkinson’s disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res. 1992;2:153–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Jaafar AF, Gray WK, Porter B, et al. A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson’s disease. BMC Neurol. 2010;10:124.Google Scholar
  25. 25.
    Eadie M, Tyrer JH. Alimentary disorders in parkinsonism. Aust Ann Med. 1965;14:13–22.PubMedGoogle Scholar
  26. 26.
    Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord. 1991;6:151–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Tumilasci OR, Cersosimo MG, Belforte JE, et al. Quantitative study of salivary secretion in Parkinson’s disease. Mov Disord. 2006;21:660–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Nobrega AC, Rodrigues B, Torres AC, et al. Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease? Parkinsonism Relat Disord. 2008;14:243–5.PubMedCrossRefGoogle Scholar
  29. 29.
    • Arbouw ME, Movig KL, Koopmann M, et al.: Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010;74:1203–7. This provides level I evidence for glycopyrrolate to treat sialorrhea in PD.PubMedCrossRefGoogle Scholar
  30. 30.
    • Thomsen TR, Galpern WR, Asante A, et al.: Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord. 2007;22:2268–73. This provides level I evidence for ipratropium to treat sialorrhea in PD.PubMedCrossRefGoogle Scholar
  31. 31.
    Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17:1318–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Ondo W, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37–40.PubMedGoogle Scholar
  33. 33.
    Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:704–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Edwards L, Quigley EM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinson’s disease: and 18-month follow-up study. Mov Disord. 1993;8:83–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Ali GN, Wallace KL, Schwartz R, et al. Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson’s disease. Gastroenterology. 1996;110:383–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Castell JA, Johnston BT, Colcher A, et al. Manometric abnormalities of the oesophagus in patients with Parkinson’s disease. Neurogastroenterol Motil. 2001;13:361–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Stroudley J, Walsh M. Radiological assessment of dysphagia in Parkinson’s disease. Br J Radiol. 1991;64:890–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Fuh JL, Lee RC, Wang SJ, et al. Swallowing difficulty in Parkinson’s disease. Clin Neurol Neurosurg. 1997;99:106–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Leopold NA, Kagel MC. Laryngeal deglutition movement in Parkinson’s disease. Neurology. 1997;48:373–6.PubMedGoogle Scholar
  40. 40.
    Potulska A, Friedman A, Krolicki L, et al. Swallowing disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9:349–53.PubMedCrossRefGoogle Scholar
  41. 41.
    Bassotti G, Germani U, Pagliaricci S, et al. Esophageal manometric abnormalities in Parkinson’s disease. Dysphagia. 1998;13:28–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord. 1996;11:729–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson’s disease. Scand J Rehabil Med. 2000;32:11–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson’s disease. Neurogastroenterol Motil. 2006;18:369–75.PubMedCrossRefGoogle Scholar
  45. 45.
    Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson’s Disease. Mov Disord. 2001;16:1041–47.PubMedCrossRefGoogle Scholar
  46. 46.
    Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidine therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord. 1997;12:952–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Djaldetti R, Koren M, Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson’s disease. Mov Disord. 1995;10:81–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease. Parkinsonism Relat Disord. 2005;11:499–502.PubMedCrossRefGoogle Scholar
  49. 49.
    Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin Wochenschr. 1991;69:906–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:268–72.PubMedCrossRefGoogle Scholar
  51. 51.
    Edwards LL, Quigley EM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson’s disease. Am J Gastroenterol. 1994;89:15–25.PubMedGoogle Scholar
  52. 52.
    Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456–62.PubMedGoogle Scholar
  53. 53.
    Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22:1581–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Petrovitch H, Abbott RD, Ross GW, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009;24:371–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Ashraf W, Pfeiffer R, Park F, et al. Constipation in Parkinson’s Disease: objective assessment and response to psyllium. Mov Disord. 1997;12:946–51.PubMedCrossRefGoogle Scholar
  56. 56.
    Eichhorn T, Oertel W. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord. 2001;16:1176–7.PubMedCrossRefGoogle Scholar
  57. 57.
    • Zangaglia R, Martignoni E, Glorioso M, et al.: Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord. 2007;22:1239–44. This provides level I evidence for polyethylene glycol to treat constipation in PD.PubMedCrossRefGoogle Scholar
  58. 58.
    Jost W, Schimrigk K. Cisapride treatment of constipation in Parkinson’s disease. Mov Disord. 1993;8:339–43.PubMedCrossRefGoogle Scholar
  59. 59.
    Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameloriates constipation in parkinsonian patients. Mov Disord. 2005;20:680–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Morgan J, Sethi K. Tegaserod in constipation associated with Parkinson Disease. Clin Neuropharmacol. 2007;30:52–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol. 1989;46:1061–4.PubMedGoogle Scholar
  62. 62.
    Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry. 1988;51:1503–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol. 1993;33:490–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Albanese A, Maria G, Bentivoglio AR, et al. Severe constipation in Parkinson’s disease relieved by botulinum toxin. Mov Disord. 1997;12:764–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Cadeddu F, Bentivoglio A, Brandara F, et al. Outlet type constipation in Parkinson’s disease:results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997–1003.PubMedCrossRefGoogle Scholar
  66. 66.
    Wiley J, Owyang C. Dopaminergic modulation of rectosigmoid motility: action of domperidone. J Pharmacol Exp Ther. 1987;242:548–51.PubMedGoogle Scholar
  67. 67.
    Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21:524–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Ciucci MR. Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson’s Disease. Mov Disord. 2008;23:676–83.PubMedCrossRefGoogle Scholar
  69. 69.
    Zibetti M, Torre E, Cinquepalmi A, et al. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol. 2007;58:218–23.PubMedCrossRefGoogle Scholar
  70. 70.
    Tuite PJ, Maxwell RE, Ikramuddin S, et al. Weight and body mass index in Parkinson’s disease patients after deep brain stimulation surgery. Parkinsonism Relat Disord. 2005;11:247–52.PubMedCrossRefGoogle Scholar
  71. 71.
    Walker HC, Lyerly M, Cutter G, et al. Weight changes associated with unilateral STN DBS and advanced PD. Parkinsonism Relat Disord. 2009;15:709–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Emory UniversityAtlantaUSA
  2. 2.505H Whitehead Biomedical Research BuildingEmory UniversityAtlantaUSA

Personalised recommendations